Login / Signup

Trifluridine/tipiracil+bevacizumab (BEV) vs. fluoropyrimidine-irinotecan+BEV as second-line therapy for metastatic colorectal cancer: a randomised noninferiority trial.

Yasutoshi KubokiTetsuji TerazawaToshiki MasuishiMasato NakamuraJun WatanabeHitoshi OjimaAkitaka MakiyamaMasahito KotakaHiroki HaraYoshinori KagawaNaotoshi SugimotoHiasto KawakamiAtsuo TakashimaTakeshi KajiwaraEiji OkiYu SunakawaSoichiro IshiharaHiroya TaniguchiTakako Eguchi NakajimaSatoshi MoritaKuniaki ShiraoNaruhito TakenakaDaisuke OzawaTakayuki Yoshino
Published in: British journal of cancer (2023)
JapicCTI-173618, jRCTs031180122.
Keyphrases
  • metastatic colorectal cancer
  • clinical trial
  • study protocol
  • open label
  • phase iii
  • phase ii
  • double blind
  • placebo controlled
  • randomized controlled trial